Investor ELI LILLY & Co
13D/G Filings

This page shows a list of all the recent 13D/G filings made by ELI LILLY & Co . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2023-08-14 13D/A US82657L2060 / SIGILON THERAPEUTICS INC 100
2023-07-07 13D SGTX / Sigilon Therapeutics Inc 2,744,443 1,008,830
2023-01-27 13G/A DTIL / Precision BioSciences, Inc. 3,762,190 3,762,190
2023-01-27 13G/A ACIU / AC Immune SA 3,615,328 3,615,328
2022-12-23 13G/A PRQR / ProQR Therapeutics N.V. 3,989,976 13,371,562
2022-12-01 13D/A AKUS / Akouos Inc 9,639,189 100
2022-10-27 13D AKUS / Akouos Inc 9,639,189
2022-02-10 13G/A FMTX / Forma Therapeutics Holdings Inc 339,191
2022-02-10 13G/A SURF / Surface Oncology Inc 1,593,997
2022-02-10 13G/A RNA / Avidity Biosciences, Inc. 2,319,396 2,319,396
2022-02-10 13G/A LPTX / Leap Therapeutics, Inc. 2,632,221 3,151,605
2022-02-10 13G/A AGLE / Aeglea BioTherapeutics Inc 2,568,543 1,526,516
2022-02-10 13G IMCR / Immunocore Holdings plc - Depositary Receipt (Common Stock) 2,548,145
2021-12-13 13G FHTX / Foghorn Therapeutics Inc. 4,000,000
2021-09-10 13G PRQR / ProQR Therapeutics N.V. 3,989,976
2021-02-12 13G ACIU / AC Immune SA 3,615,328
2021-02-12 13G RNA / Avidity Biosciences, Inc. 2,319,396
2021-02-12 13G SGTX / Sigilon Therapeutics Inc 2,744,443
2021-01-22 13D/A US74140Y1010 / Prevail Therapeutics Inc. 18,858,511 100
2021-01-08 13G DTIL / Precision BioSciences, Inc. 3,762,190
2020-12-22 13D US74140Y1010 / Prevail Therapeutics Inc. 18,858,511
2020-02-20 13D/A DERM / Journey Medical Corporation 7,057,984 54,701,996
2020-01-10 13D DERM / Journey Medical Corporation 7,057,984
2019-05-03 13G/A ZYME / Zymeworks Inc. 3,148,647 1,545,559
2019-02-15 13D/A LOXO / Loxo Oncology, Inc. 2,038,920 30,788,343
2019-02-14 13G/A LPTX / Leap Therapeutics, Inc. 2,301,000 2,632,221
2019-02-14 13G ELAN / Elanco Animal Health Incorporated 293,290,000
2019-02-14 13G/A ZYME / Zymeworks Inc. 3,957,085 3,148,647
2019-01-15 13D LOXO / Loxo Oncology, Inc. 2,038,920
2018-12-20 13D DRNA / Dicerna Pharmaceuticals Inc 5,414,185
2018-02-14 13G/A ZSAN / Zosano Pharma Corp 1,363,636
2018-02-14 13G ZYME / Zymeworks Inc. 3,957,085
2017-11-22 13G LPTX / Leap Therapeutics, Inc. 2,301,000
2017-06-07 13G/A 451731103 / Ignyta, Inc. 2,713,000 1,886,777
2017-03-01 13D/A CLCD / CoLucid Pharmaceuticals, Inc. 54,683 100
2017-01-27 13D CLCD / CoLucid Pharmaceuticals, Inc. 54,683
2016-04-22 13G AGLE / Aeglea BioTherapeutics Inc 2,568,543
2015-11-16 13G 451731103 / Ignyta, Inc. 2,713,000
2015-02-17 13G DARE / Daré Bioscience, Inc. 2,356,227
2015-02-17 13G/A RCPT / Receptos, Inc. 967,067
2015-02-12 13G/A UTHR / United Therapeutics Corporation
2015-02-09 13G ZSAN / Zosano Pharma Corp 1,363,636
2014-11-24 13G CHRS / Coherus Oncology, Inc. 3,042,019
2013-11-21 13G/A RCPT / Receptos, Inc. 2,081,210
2012-02-16 13G/A UTHR / United Therapeutics Corporation 3,150,836